M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B BioPharma DiveAssertio s latest offer represents a roughly 31% premium over an initial acquisition proposal.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioPharma Dive Assertio s latest offer represents a roughly 31% premium over an initial acquisition proposal. Read full story Post navigation Previous: ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body compositionNext: UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
